Navigation Links
Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
Date:12/22/2009

unmet medical needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and main
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
2. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
3. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
4. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
5. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
6. Resverlogix Provides Quarterly Update
7. Resverlogix Board of Directors Update
8. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
9. Resverlogix Announces Closing of Debt Redemption
10. Resverlogix Eliminates Sixty Percent of Remaining Debt
11. Resverlogix Issues a Management Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 Trigemina, Inc., a ... non-narcotic, nasally delivered, analgesic drug products, announced today that ... the position of chief medical officer. Dr. Kori brings ... much of which has been focused in the neuroscience ... add Dr. Kori to our clinical team given his ...
(Date:8/4/2015)...  Blueprint Medicines (NASDAQ: BPMC ), a leader ... genomically defined diseases, today announced that Jeffrey Albers ... at the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, ... A live webcast of the event will be available ... website at www.blueprintmedicines.com . An archived replay of ...
(Date:8/4/2015)... ANGELES , Aug. 4, 2015   California ... the recent acquisition of LifeLine Cryogenics, an east coast ... New York tristate area. LifeLine ... and all prepaid contracts will be honored. ... cryogenics services, offering storage of sperm, eggs, embryos, and ...
(Date:8/3/2015)... Aug. 3, 2015  ArroGen Group, an integrated ... Fingerprint Molecular Identification™ (FMID) technology Aug. 2-8 at ... Sacramento, Calif. ... enable law enforcement agents, district attorneys and government ... suspects. By analyzing chemical residues on ...
Breaking Biology Technology:Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 2Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 3FamilyCord Announces Acquisition of LifeLine Cryogenics 2ArroGen Previews New Fingerprint Molecular Identification Technology 2
... Madison, Wis. -- Rita Colwell, former director of ... Pollution and Human Health" at 5:30 p.m. Monday, Oct. ... of Wisconsin-Madison's Memorial Union. , ,Colwell headed the NSF ... Inc., and is a distinguished professor at the University ...
... Wis. -- Three Wisconsin businesses will receive funding ... Commerce Technology Assistance Grant (TAG) and Technology Venture Fund ... , SonoPlot, Inc. is a Madison company established in ... $100,000 TVF loan to purchase equipment and develop a ...
... help of new silicon-based compounds, scientists - and patients ... the tiny lithium batteries used in implantable devices to ... lithium battery is the workhorse of implantable devices, which ... the central nervous system make critical connections in, for ...
Cached Biology Technology:New battery technology helps stimulate nerves 2New battery technology helps stimulate nerves 3
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015  Synaptics ... interface solutions, announced today that it will report financial ... on Thursday, July 30, 2015 after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... cancer globally, and the fourth most fatal, with a ... year. The poor prognosis of pancreatic cancer patients has ... to treatment, which is not being met by the ... contains an array of products with varying molecule types ...
(Date:7/7/2015)... , June 30, 2015 ... has announced the addition of the "Capacitive ... offering. To this date, fingerprint sensing ... technology and fingerprint sensors are well developed. This ... sensing technology. The domain of capacitive ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... $5 million National Science Foundation (NSF) grant to upgrade ... Owens Valley Solar Array (OVSA) http://www.ovsa.njit.edu/ ... is expected to help scientists better understand the nature ... the military. "Space weather incidents such as ...
... What:,Based on what we know about smoking, diet, ... estimate we could prevent approximately half of all ... Association for Cancer Research will host its Ninth ... Research at the Pennsylvania Convention Center, located in ...
... Bad Hofgastein, 6 October 2010 -- European patients are in ... medically assisted reproduction (MAR) treatment, experts from the European Society ... European Health Forum Gastein (EHFG). The EHFG is ... EU. This year it has attracted about 600 decision-makers from ...
Cached Biology News:$5 million NSF grant will upgrade and expand NJIT radio telescope array 2$5 million NSF grant will upgrade and expand NJIT radio telescope array 3Reproductive health: Checkerboard of infertility treatment in Europe 2Reproductive health: Checkerboard of infertility treatment in Europe 3
...
Chicken polyclonal to ADI1 ( Abpromise for all tested applications). Antigen: Full length native protein (purified), corresponding to amino acids 1-179 of Human ADI1. Entrez GeneID: 55256 ...
ABI Plant AFLP Kits • EcoRI-ACA AFLP Amplification Primers...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Biology Products: